MedPath

Difference between Patoladigana Vasti versus standard control Triphala Kwath Lekhan Vasti in the management of Dyslipidemia Medoroga

Phase 3
Conditions
Health Condition 1: E889- Metabolic disorder, unspecified
Registration Number
CTRI/2024/02/062741
Lead Sponsor
Mahatma Gandhi Ayurveda College Hospital and Research Centre Salod Wardha
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Newly Diagnosed Dyslipedemia Patients with Serum Cholesterol > 20 mg/dl

Serum Triglycerides > 150 mg/dl

Serum HDL > 40 mg/dl

Serum VLDL > 30 mg/dl

Patient with Controlled Hypertension

Patient with Controlled type II Diabetes

Exclusion Criteria

Patients with age < 20 years and > 60 years

Serum Triglycerides > 150 mg/dl

Serum HDL < 40 mg/dl

Serum VLDL < 30 mg/dl

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
to asses the efficacy of Patoladi Vasti in Serum total Cholesterol level Triglycerides LDL HDL VLDLTimepoint: 7 Weeks
Secondary Outcome Measures
NameTimeMethod
to asses the efficacy of triphala kwath lekhan Vasti in Serum total Cholesterol level Triglycerides LDL HDL VLDLTimepoint: 1 week 7th week
© Copyright 2025. All Rights Reserved by MedPath